KAT5 Negatively regulates the proliferation of prostate cancer LNCaP cells via the caspase 3-dependent apoptosis pathway

Chul-Hong Kim and Dong Ho Lee
Department of Life Science, Chung-Ang University, Seoul, Republic of Korea

ABSTRACT
Prostate cancer is one of the most common cancers in men over the age of sixty. Lysine acetyltransferase 5 (KAT5) is a histone acetyltransferase involved in transcriptional regulation, DNA repair, and cell signaling pathways. Previous studies have shown that KAT5 expression is reduced in the cytoplasm of the prostate cancer cell line LNCaP when exposed to androgen. Moreover, KAT5 has been reported to have a role in the molecular pathway leading to androgen-independent prostate cancer after long-term androgen deprivation therapy. Here, we showed that KAT5 expression was significantly reduced in prostate cancer tissues and cell lines by using the public databases Oncomine and Human Protein Atlas. Reduced KAT5 expression was significantly associated with high mortality in prostate cancer patients. Furthermore, KAT5 overexpression increased the level of apoptotic markers, such as cleaved-caspase 3, in LNCaP cells, thus enhancing the apoptotic death of LNCaP cells. Taken together, KAT5 induced apoptosis in prostate cancer cells via the caspase-3 pathway, indicating that KAT5 could be a gene therapy target for prostate cancer.

Introduction
Androgen receptors (ARs) play essential roles in the development and progression of prostate cancer. In prostate cancer cells, ARs modulate the expression of proteins regulating the cell cycle, survival, and growth. AR activity appears to be closely regulated by histone acetylation in prostate cancer (He et al. 2013). Co-activators such as KAT5 (lysine acetyltransferase 5) and co-repressors such as the HDAC family bind the AR complex to facilitate or prevent the transcription of AR target genes via their respective histone acetyl transferase (HAT) or histone deacetylase (HDAC) activities (Fu et al. 2000; Korkmaz et al. 2004; Dai et al. 2007). Moreover, altered AR histone modification profiles have been reported in prostate cancer (Seligson et al. 2005).

KAT5 (lysine acetyltransferase 5) was originally identified as TIP60 (HIV-1 Tat Interactive Protein, 60 kDa) by Kamine et al. (Kamine et al. 1996). Through large-scale RNAi screening it was discovered that KAT5 was involved in an important part of the process of p53-dependent cell growth arrest (Bem et al. 2004). Recently, Gregoire et al., reported that KAT5 is a regulator of the mesenchymal-to-epithelial transition linked to the mesenchymal phenotype of MDA-MB-231 breast cancer cells (Gregoire et al. 2016). Moreover, KAT5 expression was significantly increased in clinical prostate cancer tissues and castration-resistant prostate cancer cells, with its expression level closely related to disease progression (Halkidou et al. 2003). KAT5 is an emerging candidate therapeutic target in cancer, with several inhibitors having been developed recently (Furdas et al. 2012; Farria et al. 2015); however, the functional role of KAT5 in prostate cancer has not yet been fully elucidated.

In this study, we found that KAT5 expression was significantly reduced in prostate cancer tissues and cell lines. Moreover, low levels of endogenous KAT5 in the prostate cancer cell line were closely related with the low expression of apoptosis-related proteins in the same cell line. Furthermore, ectopic KAT5 expression significantly induced the apoptotic cell death of prostate cancer cells. Here, we showed that KAT5 negatively regulates the growth of prostate cancer cells, suggesting that KAT5 could be a therapeutic candidate for prostate cancer therapy.

Materials and methods
Cell culture and transfection
The human prostate cancer cell line LNCaP was obtained from Korea Cell Line Bank (Seoul, Korea). LNCaP cells were grown in RPMI 1640 (Welgene, Seoul, Korea)
supplemented with 10% fetal bovine serum (FBS; Welgene, Seoul, Korea), 1% penicillin–streptomycin (Welgene, Seoul, Korea) at 37°C in a humidified, 5% CO₂ atmosphere. Cells were transfected with different plasmid DNA constructs using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

**Western blotting**

The collected cells were lysed with a buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris–HCl (pH 7.5), 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, and 1 mM PMSF by vortexing. The cell suspensions were incubated on the ice for 3 min and centrifuged at 13,000 rpm at 4°C for 10 min. The protein samples were electrophoresed on a 10% SDS-PAGE and transferred to a nitrocellulose membrane (Protran™; Whatman, Maidstone, UK). After incubation with 5% skim milk in TBST (20 mM Tris–HCl (pH 7.6), 137 mM NaCl and 0.1% Tween-20) for 1 h, the membrane was washed 3 times with TBST and incubated with antibodies against PARP-1 (1:1000, sc-56197, Santa Cruz), Caspase 3 (1:1000, #9662, Cell Signaling), Bax (1:500, #2772, Cell Signaling), Cytochrome C (1:1000, sc-13156, Santa Cruz), Bcl-w (1:500, sc-11422, Santa Cruz), Bcl-2 (1:500, sc-7382, Santa Cruz), p21 (1:1000, sc-6246, Santa Cruz), β-actin (1:1000, sc-47778, Santa Cruz), KAT5 (1:1000, sc-5725, Santa Cruz) at room temperature. Membranes were washed three times for 10 min with TBST and incubated with a 1:5000 dilution of horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies for 1 h. Blots were washed with TBST three times and developed with the Western blotting luminol reagent (sc-2048, Santa Cruz) according to the manufacturer's protocols.

**RNA preparation and RT-qPCR**

Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer’s specifications. Contaminated genomic DNA was removed from 5 μg of total RNA by incubation with 10 units of RNase-free DNase I (New England Biolabs) and 2 units of RNase inhibitor (New England Biolabs) in DEPC-treated water. The reaction mixture was incubated for 1 h at 37°C and then for 10 min at 60°C. A quantitative RT–PCR (qRT-PCR) method was used to measure gene expression in cells. Oligo-dT (TAKARA, Seoul, Korea) was used as the primer in the first step of cDNA synthesis. Total RNA (1 μg) was combined with 1 μl of oligo dT, and H₂O and then preheated at 70°C for 5 min to denature the secondary structures. The mixture was then cooled rapidly to 4°C, after which 2 μl of 10X reverse-transcriptase buffer, 10 mM DTT, and 200 units of reverse transcriptase (TAKARA, Seoul, Korea) was added to give a total volume of 20 μl. The reverse-transcriptase mix was incubated at 40°C for 1 h, after which it was stopped by heating at 94°C for 30 sec. The cDNA stock was stored at -20°C. The specificity of each of the amplified products was confirmed by melting curve analysis. For Real-Time PCR, the iQ SYBR Green PCR Supermix (Bio-Rad) and the CFX96 Real-time PCR detection system (Bio-Rad) were used to detect the Real-time quantitative PCR products of reverse-transcribed cDNA samples according to the manufacturer’s instructions.

**Cell viability assay**

LNCaP cells were seeded at a density of 5 × 10⁴ cells per well in six well plates in RPMI 1640 with 1% FBS and transfected with indicated expression vectors using Lipofectamine. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) was dissolved at 5 mg/ml in PBS solution. Two days after transfection, 400 μl of MTT solution was directly added to the medium and the cells were incubated for an additional 4 h. After removal of the medium, 4 ml of 0.04 N hydrochloric acid in isopropanol was added to each well and the optical density of the destained solution was measured on a Multiscan Go microplate reader (Waltham, MA) at a wavelength of 570 nm.

**Cell cycle analysis**

LNCaP cells were trypsinized, and the resulting cell suspensions were centrifuged at 3000 rpm for 3 min. The cells were fixed for 1 h in 70% ethanol at 4°C and centrifuged at 3000 rpm for 3 min, and the pellets were washed with ice-cold PBS. Cell pellets were then resuspended in 0.1 ml of PBS containing 100 μg/ml RNase A for 1 h at 37°C. After that, 50 μg/ml of propidium iodide (Sigma-Aldrich) was added and then incubated for 15 min at RT in a dark. PI-stained cells were analyzed by BD Accuri™ C6 Plus (BD FACS, San Jose, CA). At least 10,000 cells were used for each analysis, and the results were displayed as histograms. The percentage of cell distribution in Sub-G1, G0/G1, S and G2/M phase were measured, and the results were analyzed by the BD Accuri™ C6 Plus software for cell cycle profile.

**Annexin V and propidium iodide (PI) staining for apoptosis assay**

To assess the apoptosis, the cells were harvested and centrifuged at 3000 rpm for 3 min. cell proportions were detected using FITC Annexin V Apoptosis Detection Kit I (BD pharmentgen, La Jolla, CA) according to the
manufacturer’s instructions. The cell pellets were washed with 1X PBS and resuspended in 100 μl of Annexin V binding buffer. Cells were labeled with 5 μl of Annexin V-Alexa Fluor 488 and/or PI. After 15 min incubation in a dark, 400 μl of Annexin V binding buffer was added to wash the Annexin/PI stained cells. A minimum of 10,000 cells per sample was analyzed using BD Accuri™ C6 Plus (BD FACS, San Jose, CA).

Cell proliferation assay

For the assay of colony forming efficiency in soft agar, transfected LNCaP cells were counted using a hemocytometer. 5 x 10^3 cells in 1 ml growth medium containing 0.35% Noble agar (DIFCO Laboratories, Detroit, MI, USA) and G418 (800 μg/ml) were incubated in a 60 mm culture dish overlaid on 1.5 ml of 0.5% base agar medium. Cells were incubated at 37°C in a moist atmosphere of 95% air and 5% CO₂ and 4 weeks later the number of colonies was counted after 0.005% crystal violet staining.

Statistical analysis

Statistical analysis of variances between two different experimental groups was performed with Tukey’s post hoc comparison test using SPSS (Version 11.5). All experiments were repeated at least three times. The levels are considered significant at a P value of < 0.05 (*) very significant at a P value of < 0.01(**), definitely significant for at a P value of < 0.001(***), or not significant (n.s.).

Results

Low KAT5 expression in prostate cancer tissues and cell line

Androgen receptor (AR) co-regulators modify AR gene transactivation and prostate cell survival via acetylation,
phosphorylation, ubiquitination, and sumoylation (van der Steen et al. 2013). The ubiquitously expressed acetyltransferase, KAT5, is expected to play an essential role in prostate cancer. In order to determine the possible role of KAT5 in prostate cancer, we investigated KAT5 expression levels in prostate cancer patients compared to corresponding normal individuals using the OncoMine database (normal; n = 8, prostate cancer patients; n = 32). As shown in Figure 1(A), the KAT5 expression profile was significantly lower in prostate cancer patients than in the normal group. The Human Protein Atlas database also showed that KAT5 protein expression was significantly lower in prostate cancer tissues than in normal tissues (Figure 1(B)). Moreover, the reduced KAT5 expression correlated with low survival rate in prostate cancer patients (Figure 1(C)). Next, we compared the mRNA and protein levels of KAT5 in various prostate cancer cell lines and in a normal human prostate epithelial cell line, RWPE-1. KAT5 expression was markedly lower in the human prostate cancer cell lines LNCaP and PC-3 than in the RWPE-1 cells. Interestingly, low KAT5 expression in the prostate cancer cell line (LNCaP) was closely related with low expression levels of Bax, an apoptotic marker; however, Bax protein expression levels were not affected in other prostate cell lines (PC-3 and DU-145; data not shown).

**Ectopic KAT5 expression reduces prostate cancer cell proliferation**

To investigate the effect of KAT5 expression on prostate cancer cell proliferation, plasmids containing the full length KAT5 gene were transfected into the human prostate cancer cell line, LNCaP. KAT5 overexpression reduced the cellular proliferation rate compared to the vehicle-transfected control group. Colony forming ability was severely reduced in the KAT5-overexpressing cells (Figure 2(A and B)), with the number of colonies...
significantly reduced by KAT5 overexpression in LNCaP cells. However, the cell cycle was not affected by KAT5 overexpression (Figure 2(C)).

**KAT5 induces the apoptotic death of prostate cancer cells**

Since the reduced growth of prostate cancer cells was not due to changes in the cell cycle, we examined apoptotic cell death in LNCaP cells following KAT5 overexpression. Staining LNCaP cells with PI and Annexin-V revealed that both early and late apoptotic populations were significantly enhanced by KAT5 overexpression (Figure 3(A)). Moreover, the levels of apoptotic proteins such as cleaved caspase-3, cleaved PARP, and cytosolic cytochrome C increased by approximately 4.3-, 2.7-, and 1.6-fold following ectopic KAT5 expression in LNCaP cells. However, the levels of pro-survival family members (Bcl2, Bcl-w) was not affected by KAT5 overexpression (Figure 3(B)).

**Figure 3.** KAT5 increased apoptotic LNCaP cell death. (A) Forty-eight hours after transfection with the indicated plasmid, cells were subjected to propidium iodide (PI) or PI/Annexin-V double staining and FACS analysis was performed. (B) After cells were transfected with plasmids encoding FLAG or FALG-tagged KAT5, the expression of apoptosis-related proteins (cytochrome C, caspase 3, PARP, Bcl-2, Bcl-w) was confirmed by western blotting with β-actin as a loading control. (C) Schematic diagram of the molecular mechanism of the KAT5-induced apoptosis pathway in LNCaP prostate adenocarcinoma cells. KAT5 expression increases cytochrome C release and the activation of caspase 3 and cleavage poly-ADP-ribose polymerase (PARP), leading to apoptosis.
Discussion

The lysine acetyltransferase KAT5 is a member of a large superfamily of epigenetic regulatory proteins that play a number of important cellular roles and are emerging as candidate targets for cancer therapy (Farria et al. 2015). Therefore, we examined the function of KAT5 in prostate cancer cells. Ectopic KAT5 expression enhanced the expression of proapoptotic proteins including Bax, cleaved caspase-3, cytosolic cytochrome c, and PARP, thus increasing the early and late apoptotic populations of prostate cancer cells (Figure 3). Our results clearly demonstrated that endogenous KAT5 levels are reduced in aggressive prostate cancer tissue (Human Protein Atlas data and Oncomine database; Figure 1).

Although KAT5 overexpression in LNCaP cells reduced cellular proliferation and colony formation, KAT5 did not slow the cell cycle (Figure 2). Under genotoxic stress conditions, KAT5 can regulate the cell cycle at the intra-S-phase checkpoint alongside ATM kinase (Ortega-Atienza et al. 2015); however, ectopic KAT5 expression did not affect cell cycle regulation in prostate cancer cells. Instead, KAT5 expression significantly increased Bax, cleaved caspase-3, cleaved PARP, and cytosolic cytochrome C levels via an intrinsic apoptosis pathway (Figure 3(C)). In particular, KAT5 plays a crucial role in p53-dependent apoptosis by specifically acetylating lysine 120 (K120) of the p53 DNA-binding domain; however, p53 regulates both cell-cycle arrest and apoptosis depending on the cellular context (Tang et al. 2006). The corresponding acetylation-defective tumor mutant (K120R) abrogates p53-mediated apoptosis, but not growth arrest in cancer cells (Tang et al. 2006), suggesting that KAT5 induces the death of prostate cancer cells via the p53-mediated intrinsic apoptosis pathway. Since p53 levels were not evaluated in this study, future investigations should elucidate whether p53 is involved in KAT5-induced prostate cancer cell death.

Histone deacetylases (HDACs), such as HDAC1, 2, 3 and 4, are highly expressed in prostate cancer tissues and their functions are over-activated. In patients with prostate cancer, high HDAC expression and hyperactivation were correlated with poor prognosis. HDAC overexpression results in accelerated proliferation, delayed differentiation, and aggressive phenotype in prostate cancer cells (Halkidou et al. 2004; Weichert et al. 2008). Consequently, HDAC function has been considered a potential therapeutic target for prostate cancer treatment. Clinical studies with HDAC inhibitors have shown significantly decreased levels of prostate-specific antigens (PSAs) in some patients (Munster et al. 2009).

Here, we found that KAT5 proteins were barely detectable in the prostate cancer cell line and prostate cancer tissues, similar to the pattern observed in a breast cancer cohort study (McGuire et al. 2019). In contrast, KAT5 is significantly overexpressed in malignant pleural mesothelioma (MPM) (Cregan et al. 2016). Although, much remains to be elucidated regarding the molecular mechanisms of KAT5 in prostate cancer initiation and progression, the correlation of low KAT5 expression with a higher chance of tumor aggressiveness suggest that KAT5 is an attractive biomarker of prostate cancer. Thus, our results may provide a useful drug target for the treatment of patients with prostate cancer.

Acknowledgements

We thank Prof. Jung-Woong Kim (Department of Life Science, Chung-Ang University, Seoul, South Korea) who allowed us to perform experiments at the Genome Dynamics Laboratory for this study.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

Bens K, Hijnmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, et al. 2004. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 428:431–437.
Cregan S, McDonagh L, Gao Y, Barr MP, O’Byrne KJ, Finn SP, Cuffe S, Gray SG. 2016. KAT5 (Tip60) is a potent therapeutic target in malignant pleural mesothelioma. Int J Oncol. 48:1290–1296.
Dai Y, Ngo D, Forman LW, Qin DC, Jacob J, Faller DV. 2007. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol. 21:1807–1821.
Farria A, Li W, Dent SYR. 2015. KATs in cancer: functions and therapies. Oncogene. 34:4901–4913.
Fu MF, Wang CG, Reuten AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG. 2000. P300 and p300/CAMP-response element-bridging protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 275:20853–20860.
Furdas SD, Kannan S, Sippl W, Jung M. 2012. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch Pharm (Weinheim). 345:7–21.
Gregoire JM, Fleury L, Salazar-Cardozo C, Alby F, Masson V, Arimondo PB, Asselle F. 2016. Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells. BMC Cancer. 16:700.
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. 2004. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 59:177–189.

Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. 2003. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 22:2466–2477.

He W, Zhang MG, Wang XJ, Zhong S, Shao Y, Zhu Y, Shen ZJ. 2013. KAT5 and KAT6B are in positive regulation on cell proliferation of prostate cancer through PI3K-AKT signaling. Int J Clin Exp Patho. 6:2864–2871.

Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G. 1996. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 tat transactivator. Virology. 216:357–366.

Korkmaz CG, Fronsdal K, Zhang Y, Lorenzo PI, Saatcioglu F. 2004. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation - rescue of transcriptionally compromised mutants. J Endocrinol. 182:377–389.

McGuire A, Casey MC, Shalaby A, Kalinina O, Curran C, Webber M, Callagy G, Holian E, Bourke E, Kerin MJ, et al. 2019. Quantifying Tip60 (Kat5) stratifies breast cancer. Sci Rep-Uk. 9.

Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, et al. 2009. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 101:1044–1050.

Ortega-Atienza S, Green SE, Zhitkovich A. 2015. Proteasome activity is important for replication recovery, CHK1 phosphorylation and prevention of G2 arrest after low-dose formaldehyde. Toxicol Appl Pharmacol. 286:135–141.

Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. 2005. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 435:1262–1266.

Tang Y, Luo JY, Zhang WZ, Gu W. 2006. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 24:827–839.

van der Steen T, Tindall DJ, Huang HJ. 2013. Posttranslational Modification of the Androgen Receptor in Prostate Cancer. Int J Mol Sci. 14:14833–14859.

Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al. 2008. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 98:604–610.